PVX-410 is an experimental therapy being developed by OncoPep to treat smoldering multiple myeloma (SMM). People with SMM have changes in the bone marrow, where myeloma occurs, but do not yet have any symptoms of the disease. Most people with SMM develop multiple myeloma within five years. The current standard of care for SMM patients is “watchful waiting.”

How does PVX-410 work?

PVX-410 is a therapeutic cancer vaccine. The goal is to slow or prevent the progression of SMM into myeloma, and to prevent the damage that often occurs to patients’ bones and kidneys during SMM, even if symptoms do not appear until later.

The treatment uses multiple peptides, or short chains of amino acids (the building blocks of proteins), specific to myeloma cells to “teach” the immune system to recognize cancerous cells. It activates cytotoxic T-cells (the immune cells that kill damaged, infected, or cancerous cells) and should cause an increased immune response against myeloma cells. The use of multiple peptides can help prevent patients from developing resistance to the vaccine.

PVX-410 is designed to work both alone and in combination with other treatments. It is unclear how many doses of the vaccine will be necessary to treat SMM, or whether continued, long-term administration may be necessary.

PVX-410 in clinical trials

An open-label Phase 1b clinical trial (NCT02886065) is currently recruiting an estimated 20 patients with SMM in the U.S. to assess two different therapy combinations that include PVX-410. Patients will receive either PVX-410 and an investigational histone deacetylase (HDAC) inhibitor, citarinostat (ACY-241) or a triple combination of PVX-410, citarinostat, and the immunomodulatory treatment Revlimid (lenalidomide). The study will evaluate the safety and tolerability of the treatment combinations over a two-year period. The primary outcome measure will be the proportion of patients with adverse events. Secondary outcome measures will include immune cell activation in either treatment group.

 

Last updated: Feb. 25, 2020

***

Myeloma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Total Posts: 1
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×
Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Latest Posts
    The User does not have any posts